1929.3000 -33.30 (-1.70%)
NSE Oct 08, 2025 15:31 PM
Volume: 306.7K
 

1929.30
-1.70%
IDBI Capital
Q2FY18 revenues increased by 1.5% YoY lower than our forecast by 5.6%. EBITDA margin of 17.4% were lower than our estimates of 19.7%, mainly on the back of sales mix and higher expenses. PAT of Rs2bn, -8.6% YoY, was lower by 19.6%. For FY18, Glenmark has guided for the US business to have a run-rate of USD125mn+, however, with overall EBITDA margins of 21-22%. We are confident of Glenmark signing one out-licensing deal to help reduce debt. Key Highlights and Investment Rationale Pain continues for the US franchise...
Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2014.8
More from Glenmark Pharmaceuticals Ltd.
Recommended